1-13 of 13
Isamu Okamoto
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA

Jhanelle E. Gray, Myung-Ju Ahn, Geoffrey R. Oxnard, Frances A. Shepherd, Fumio Imamura, Ying Cheng, Isamu Okamoto, Byoung Chul Cho, Meng-Chih Lin, Yi-Long Wu, Margarita Majem, Oliver Gautschi, Michael Boyer, Krishna C. Bulusu, Aleksandra Markovets, J. Carl Barrett, Rachel Hodge, Astrid McKeown, Ryan J. Hartmaier, Juliann Chmielecki, Vassiliki A. Papadimitrakopoulou, Suresh S. Ramalingam
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (17): 3340–3351.
https://doi.org/10.1158/1078-0432.CCR-22-3146
Published: 01 September 2023
View article titled, Early Clearance of Plasma <em>Epidermal Growth Factor Receptor</em> Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA
Open the PDF for Early Clearance of Plasma <em>Epidermal Growth Factor Receptor</em> Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA in another window
Includes: Supplementary data
Journal Articles

Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer

Jhanelle E. Gray, Isamu Okamoto, Virote Sriuranpong, Johan Vansteenkiste, Fumio Imamura, Jong Seok Lee, Yong-Kek Pang, Manuel Cobo, Kazuo Kasahara, Ying Cheng, Naoyuki Nogami, Eun Kyung Cho, Wu Chou Su, Guili Zhang, Xiangning Huang, Xiaocheng Li-Sucholeiki, Brian Lentrichia, Simon Dearden, Suzanne Jenkins, Matilde Saggese, Yuri Rukazenkov, Suresh S. Ramalingam
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (22): 6644–6652.
https://doi.org/10.1158/1078-0432.CCR-19-1126
Published: 15 November 2019
View article titled, Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer
Open the PDF for Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer

Keiichi Ota, Koichi Azuma, Akihiko Kawahara, Satoshi Hattori, Eiji Iwama, Junko Tanizaki, Taishi Harada, Koichiro Matsumoto, Koichi Takayama, Shinzo Takamori, Masayoshi Kage, Tomoaki Hoshino, Yoichi Nakanishi, Isamu Okamoto
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (17): 4014–4021.
https://doi.org/10.1158/1078-0432.CCR-15-0016
Published: 31 August 2015
View article titled, Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer
Open the PDF for Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Detection of Epidermal Growth Factor Receptor Mutations in Serum DNA Using the Scorpion ARMS in Patients with Advanced Non-Small-Cell Lung Cancer

Isamu Okamoto, Hideharu Kimura, Kazuo Kasahara, Kazuto Nishio
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (19_Supplement): PL01-03.
Published: 15 August 2014
View article titled, Detection of Epidermal Growth Factor Receptor Mutations in Serum DNA Using the Scorpion ARMS in Patients with Advanced Non-Small-Cell Lung Cancer
Journal Articles

Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non–Small Cell Lung Cancer

Takeshi Yoshida, Guolin Zhang, Matthew A. Smith, Alex S. Lopez, Yun Bai, Jiannong Li, Bin Fang, John Koomen, Bhupendra Rawal, Kate J. Fisher, Ann Y. Chen, Michiko Kitano, Yume Morita, Haruka Yamaguchi, Kiyoko Shibata, Takafumi Okabe, Isamu Okamoto, Kazuhiko Nakagawa, Eric B. Haura
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (15): 4059–4074.
https://doi.org/10.1158/1078-0432.CCR-13-1559
Published: 31 July 2014
View article titled, Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non–Small Cell Lung Cancer
Open the PDF for Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer

Junko Tanizaki, Isamu Okamoto, Takafumi Okabe, Kazuko Sakai, Kaoru Tanaka, Hidetoshi Hayashi, Hiroyasu Kaneda, Ken Takezawa, Kiyoko Kuwata, Haruka Yamaguchi, Erina Hatashita, Kazuto Nishio, Kazuhiko Nakagawa
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (22): 6219–6226.
https://doi.org/10.1158/1078-0432.CCR-12-0392
Published: 14 November 2012
View article titled, Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer
Open the PDF for Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor–Induced Apoptosis in EML4-ALK–Positive Lung Cancer

Ken Takezawa, Isamu Okamoto, Kazuto Nishio, Pasi A. Jänne, Kazuhiko Nakagawa
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (8): 2140–2148.
https://doi.org/10.1158/1078-0432.CCR-10-2798
Published: 14 April 2011
View article titled, Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor–Induced Apoptosis in EML4-ALK–Positive Lung Cancer
Open the PDF for Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor–Induced Apoptosis in EML4-ALK–Positive Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Inhibition of Insulin-Like Growth Factor 1 Receptor by CP-751,871 Radiosensitizes Non–Small Cell Lung Cancer Cells

Tsutomu Iwasa, Isamu Okamoto, Minoru Suzuki, Erina Hatashita, Yuki Yamada, Masahiro Fukuoka, Koji Ono, Kazuhiko Nakagawa
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (16): 5117–5125.
https://doi.org/10.1158/1078-0432.CCR-09-0478
Published: 12 August 2009
View article titled, Inhibition of Insulin-Like Growth Factor 1 Receptor by CP-751,871 Radiosensitizes Non–Small Cell Lung Cancer Cells
Open the PDF for Inhibition of Insulin-Like Growth Factor 1 Receptor by CP-751,871 Radiosensitizes Non–Small Cell Lung Cancer Cells in another window
Includes: Supplementary data
Journal Articles

Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non–Small Cell Lung Cancer with EGFR Mutations

Satoshi Morita, Isamu Okamoto, Kunihiko Kobayashi, Koichi Yamazaki, Hajime Asahina, Akira Inoue, Koichi Hagiwara, Noriaki Sunaga, Noriko Yanagitani, Toyoaki Hida, Kimihide Yoshida, Tomonori Hirashima, Kosei Yasumoto, Kenji Sugio, Tetsuya Mitsudomi, Masahiro Fukuoka, Toshihiro Nukiwa
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (13): 4493–4498.
https://doi.org/10.1158/1078-0432.CCR-09-0391
Published: 01 July 2009
View article titled, Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non–Small Cell Lung Cancer with <em>EGFR</em> Mutations
Open the PDF for Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non–Small Cell Lung Cancer with <em>EGFR</em> Mutations in another window
Journal Articles

Phase I Study of YM155, a Novel Survivin Suppressant, in Patients with Advanced Solid Tumors

Taroh Satoh, Isamu Okamoto, Masaki Miyazaki, Ryotaroh Morinaga, Asuka Tsuya, Yoshikazu Hasegawa, Masaaki Terashima, Shinya Ueda, Masahiro Fukuoka, Yutaka Ariyoshi, Toshikazu Saito, Noriyuki Masuda, Hirokazu Watanabe, Tetsuo Taguchi, Toru Kakihara, Yumiko Aoyama, Yohko Hashimoto, Kazuhiko Nakagawa
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (11): 3872–3880.
https://doi.org/10.1158/1078-0432.CCR-08-1946
Published: 01 June 2009
View article titled, Phase I Study of YM155, a Novel Survivin Suppressant, in Patients with Advanced Solid Tumors
Open the PDF for Phase I Study of YM155, a Novel Survivin Suppressant, in Patients with Advanced Solid Tumors in another window
Journal Articles

Addition of S-1 to the Epidermal Growth Factor Receptor Inhibitor Gefitinib Overcomes Gefitinib Resistance in Non–small cell Lung Cancer Cell Lines with MET Amplification

Takafumi Okabe, Isamu Okamoto, Sayaka Tsukioka, Junji Uchida, Erina Hatashita, Yuki Yamada, Takeshi Yoshida, Kazuto Nishio, Masahiro Fukuoka, Pasi A. Jänne, Kazuhiko Nakagawa
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (3): 907–913.
https://doi.org/10.1158/1078-0432.CCR-08-2251
Published: 02 February 2009
View article titled, Addition of S-1 to the Epidermal Growth Factor Receptor Inhibitor Gefitinib Overcomes Gefitinib Resistance in Non–small cell Lung Cancer Cell Lines with <em>MET</em> Amplification
Open the PDF for Addition of S-1 to the Epidermal Growth Factor Receptor Inhibitor Gefitinib Overcomes Gefitinib Resistance in Non–small cell Lung Cancer Cell Lines with <em>MET</em> Amplification in another window
Journal Articles

Radiosensitizing Effect of YM155, a Novel Small-Molecule Survivin Suppressant, in Non–Small Cell Lung Cancer Cell Lines

Tsutomu Iwasa, Isamu Okamoto, Minoru Suzuki, Takahito Nakahara, Kentaro Yamanaka, Erina Hatashita, Yuki Yamada, Masahiro Fukuoka, Koji Ono, Kazuhiko Nakagawa
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (20): 6496–6504.
https://doi.org/10.1158/1078-0432.CCR-08-0468
Published: 16 October 2008
View article titled, Radiosensitizing Effect of YM155, a Novel Small-Molecule Survivin Suppressant, in Non–Small Cell Lung Cancer Cell Lines
Open the PDF for Radiosensitizing Effect of YM155, a Novel Small-Molecule Survivin Suppressant, in Non–Small Cell Lung Cancer Cell Lines in another window
Journal Articles

Phase II Study of Combination Therapy with S-1 and Irinotecan for Advanced Non–Small Cell Lung Cancer: West Japan Thoracic Oncology Group 3505

Isamu Okamoto, Takashi Nishimura, Masaki Miyazaki, Hiroshige Yoshioka, Akihito Kubo, Koji Takeda, Noriyuki Ebi, Shunichi Sugawara, Nobuyuki Katakami, Masahiro Fukuoka, Kazuhiko Nakagawa
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (16): 5250–5254.
https://doi.org/10.1158/1078-0432.CCR-08-0511
Published: 12 August 2008
View article titled, Phase II Study of Combination Therapy with S-1 and Irinotecan for Advanced Non–Small Cell Lung Cancer: West Japan Thoracic Oncology Group 3505
Open the PDF for Phase II Study of Combination Therapy with S-1 and Irinotecan for Advanced Non–Small Cell Lung Cancer: West Japan Thoracic Oncology Group 3505 in another window